FindTrial
Sign In

Comparison of Efficacy of Aripiprazole versus Risperidone Augmentation of Selective Serotonin Reuptake Inhibitors for Treatment of Resistant Obsessive Compulsive Disorder: A Randomized Controlled Trial

Comparison of Efficacy of Aripiprazole versus Risperidone Augmentation of Selective Serotonin Reuptake Inhibitors for Treatment of Resistant Obsessive Compulsive Disorder: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230526058298N1
Enrollment
44
Registered
2023-06-23
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive Compulsive Disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: In group A: Aripiprazole started with a 2.5 mg daily dose and will be gradually increased to 10 mg daily by the end of the second week. Treatment will be continued for 12 weeks. Interv

Sponsors

Postgraduate Medical Institute Lahore
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? Patients of age 16-65 years of either gender ? Patients diagnosed with obsessive compulsive disorder (as per operational definition) with Y-BOCS score =16.

Exclusion criteria

Exclusion criteria: ? Pregnant females ? Patient allergic to trial drugs ? Patient having an organic cause for their symptoms ? Patient with comorbid conditions that aggravate the condition or develop depression and anxiety

Design outcomes

Primary

MeasureTime frame
YALE-BROWN OBSESSIVE COMPULSIVE SCALE. Timepoint: 3 months. Method of measurement: scoring system.—

Countries

Pakistan

Contacts

Public ContactIrfan Jamil

Post graduate Medical Institute Lahore

irfanravian51@gmail.com+92 311 3773799

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026